Autres langues BioCryst Pharmaceuticals, Inc.

Actions

BCRX

US09058V1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/07/2026			Varia. 5j.	Varia. 1 janv.
9,530 ^USD	-2,16%		+1,17%	+22,18%

15/07	BioCryst Pharmaceuticals, Inc. annonce la nomination de David W. Jenkins au poste de directeur scientifique, à compter du 15 juillet 2026	CI
07/07	BIOCRYST PHARMACEUTICALS, INC. : RBC Capital Markets toujours positif	ZM

Autres langues

22/07	BioCryst to Report Second Quarter 2026 Financial Results on August 5
15/07	BioCryst Pharmaceuticals, Inc. Announces Appointment of David W. Jenkins as Chief Scientific Officer, Effective July 15, 2026
15/07	BioCryst Appoints David W. Jenkins as Chief Scientific Officer
02/07	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
29/06	BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End
29/06	BioCryst Pharmaceuticals, Inc. Discontinues Internal Discovery Programs And Closes Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark
29/06	BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark
12/06	BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment
12/06	BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
12/06	BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting
09/06	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/05	BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05	BioCryst Pharmaceuticals Presents New HAE Data From ORLADEYO And Navenibart At The European Academy Of Allergy And Clinical Immunology Annual Meeting
13/05	BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
06/05	BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	BioCryst Pharmaceuticals Swings to Q1 Net Loss, Revenue Increases; 2026 Revenue Guidance Reiterated
06/05	Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS
06/05	BioCryst: Q1 Earnings Snapshot
06/05	Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q1 Revenue $156.4M, vs. FactSet Est of $151.1M